Desensitization in Crossmatch-positive Kidney Transplant Candidates
Issued Date
2023-02-01
Resource Type
ISSN
00411337
Scopus ID
2-s2.0-85146892914
Pubmed ID
35939390
Journal Title
Transplantation
Volume
107
Issue
2
Start Page
351
End Page
360
Rights Holder(s)
SCOPUS
Bibliographic Citation
Transplantation Vol.107 No.2 (2023) , 351-360
Suggested Citation
Noble J., Jouve T., Malvezzi P., Rostaing L. Desensitization in Crossmatch-positive Kidney Transplant Candidates. Transplantation Vol.107 No.2 (2023) , 351-360. 360. doi:10.1097/TP.0000000000004279 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/82430
Title
Desensitization in Crossmatch-positive Kidney Transplant Candidates
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Access to kidney transplantation is limited by HLA-specific sensitization. Desensitization strategies enable crossmatch-positive kidney transplantation. In this review, we describe clinical experience gained over the last 20 y using desensitization strategies before kidney transplantation and describe the different tools used (both drugs and apheresis options), including IVIg, rituximab, apheresis techniques, interleukin-6 interference, proteasome inhibition, enzymatic degradation of HLA antibodies, complement inhibition, and B cytokine interference. Although access to transplantation for highly sensitized kidney transplantation candidates has been vastly improved by desensitization strategies, it remains, however, limited by the recurrence of HLA antibodies after transplantation and the occurrence of antibody-mediated rejection.